Co-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats

Journal of Huntington's Disease

Volumn 3, Issue 3, 2014, Pages 285-298

  Waters, Susanna ^a,b   Ponten, Henrik ^a   Klamer, Daniel ^a   Waters, Nicholas ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Integrative Research Laboratories   (Sweden)

Author keywords

dopaminergic stabilizer; haloperidol; Huntington's disease; locomotor activity; pridopidine; tetrabenazine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; BIOLOGICAL MARKER; DOPAMINE; HALOPERIDOL; MESSENGER RNA; PRIDOPIDINE; TETRABENAZINE; DRUG COMBINATION; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; FRONTAL CORTEX; GENE EXPRESSION; LOCOMOTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; ANIMAL; ANIMAL BEHAVIOR; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; LOCOMOTION; MALE; MOTOR ACTIVITY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRABENAZINE; TREATMENT OUTCOME;

EID: 84930188998     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140108     Document Type: Article

References (36)

1. Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat. 2007;3(5):545-51.
2. Ponten H, Kullingsjo J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010;644(1-3):88-95.
3. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine[(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propylpiperidine (ACR16) showhigh in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther. 2006;318(2):810-8.
4. Dyhring T, Nielsen EO, Sonesson C, Pettersson F, Karlsson J, Svensson P, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010;628(1-3):19-26.
5. Pettersson F, Ponten H, Waters N, Waters S, Sonesson C. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem. 2010;53(6):2510-20.
6. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963;20:140-4.
7. Nilsson M, Carlsson A, Markinhuhta KR, Sonesson C, Pettersson F, Gullme M, et al. The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: Implications for cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):677-85.
8. Andersson DR, Nissbrandt H, Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci. 2006;24(2):617-24.
9. MeyerAC, Horton DB, NeugebauerNM,Wooters TE, Nickell JR,Dwoskin LP, et al. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration. Neuropharmacology. 2011;61(4):849-56.
10. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331-73.
11. Andre VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease:Abalancing act. CNS Neurosci Ther. 2010;16(3):163-78.
12. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-75.
13. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441-66.
14. Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr. 2011;3:RRN1260.
15. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983;225(3):515-21.
16. Steward O, Worley PF. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron. 2001;30(1):227-40.
17. Kawashima T, Okuno H, Nonaka M, Adachi-Morishima A, Kyo N, Okamura M, et al. Synaptic activity-responsive element in the Arc/Arg3.1 promoter essential for synapse-tonucleus signaling in activated neurons. Proc Natl Acad Sci U S A. 2009;106(1):316-21.
18. Fumagalli F, Frasca A, Racagni G, Riva MA. Antipsychotic drugs modulate Arc expression in the rat brain. Eur Neuropsychopharmacol. 2009;19(2):109-15.
19. Waters S, Ponten H, Edling M, Svanberg B, Klamer D, Waters N. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm. 2014;In press.
20. Ponten H, Sonniksen K, Abrahamsson T, Waters N, Gustafsson B, Hanse E, et al. Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period. Brain Res Dev Brain Res. 2005;155(1):81-6.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156-9.
22. Satou T, Anderson AJ, Itoh T, TamaiY, HayashiY, Hashimoto S. Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats. Exp Toxicol Pathol. 2001;53(4):303-8.
23. Schaefer GJ, Michael RP. Drug interactions on spontaneous locomotor activity in rats. Neuroleptics and amphetamineinduced hyperactivity. Neuropharmacology. 1984;23(8):909-14.
24. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: The path to discovery. Dialogues Clin Neurosci. 2006;8(1):137-42.
25. Andersen HL, Kilpatrick IC. Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br J Pharmacol. 1996;118(2):421-7.
26. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004;483(1):45-53.
27. Roffler-Tarlov S, Sharman DF, Tegerdine P. 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the mouse striatum: A reflection of intra-and extra-neuronal metabolism of dopamine? Br J Pharmacol. 1971;42(3):343-51.
28. Waters N, Lagerkvist S, Lofberg L, Piercey M, Carlsson A. The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur J Pharmacol. 1993;242(2):151-63.
29. Gronier B, Waters S, Ponten H. The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex. J Neural Transm. 2013;120(9): 1281-94.
30. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3): 659-61.
31. Lundbeck. Highlights of Xenazine Prescribing information 2014 [cited 2014]. Available from: http://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine PI US EN.pdf.
32. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology. 1988;27(7):717-9.
33. Berardelli A, Noth. J, Thompson PD, Bollen EL, Curra A, Deuschl G, et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord. 1999;14(3): 398-403.
34. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin Ther. 2012;34(7):1487-504.
35. Armstrong MJ, Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597-603.
36. Ponten H, Kullingsjo J, Sonesson C, Waters S, Waters N, Tedroff J. The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol. 2013;698(1-3):278-85.